A pivotal trial for Taysha's Rett syndrome gene therapy, TSHA-102, has begun and has reportedly dosed its first patient. The trial's enrollment is also said to be complete, although it is unclear if the trial has concluded or if results have been announced. Some outlets suggest that the trial has shown promising results, with all patients achieving motor milestones, but the status and details of the trial's outcome are not entirely clear.